Register for our free email digests:
SmithKline Beecham
Division of GlaxoSmithKline PLC
www.sb.com
Latest From SmithKline Beecham
Bristol-Celgene: Congressional Reps Want Assurance Merger Will Not Increase Prices
Reps. Welch and Rooney urge FTC and DOJ to condition their approval of the merger on inclusion of a pricing provision.
Bristol/Celgene A Record-Setting Merger, If It Happens
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
Bristol/Celgene A Record-Setting Merger, If It Happens
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
European Loan Funds F2G's Late-Stage Novel Antifungal
€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
-
Jean-Pierre Garnier, CEO
John Coombe, CFO
James Niedel, MD, PhD, CSO & CTO
Tadataka Yamada, MD, Chmn., R&D
Russell Greig, SVP, Global Bus. Dev.
Robert Ingram, Pres. & COO, Pharm. Oper. - Contact Info
-
SmithKline Beecham
Phone: (215) 751-4000
One Franklin Plaza
P.O. Box 7929 Philadelphia, PA 19101-
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice